GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Price-to-Owner-Earnings

Evolutionary Genomics (Evolutionary Genomics) Price-to-Owner-Earnings : (As of Jun. 21, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Price-to-Owner-Earnings?

As of today (2024-06-21), Evolutionary Genomics's share price is $0.45. Evolutionary Genomics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Evolutionary Genomics's Price-to-Owner-Earnings or its related term are showing as below:


FNAM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.85
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-21), Evolutionary Genomics's share price is $0.45. Evolutionary Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.34. Therefore, Evolutionary Genomics's PE Ratio for today is At Loss.

As of today (2024-06-21), Evolutionary Genomics's share price is $0.45. Evolutionary Genomics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.34. Therefore, Evolutionary Genomics's PE Ratio without NRI for today is At Loss.


Evolutionary Genomics Price-to-Owner-Earnings Historical Data

The historical data trend for Evolutionary Genomics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Price-to-Owner-Earnings Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evolutionary Genomics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Evolutionary Genomics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolutionary Genomics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Price-to-Owner-Earnings falls into.



Evolutionary Genomics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Evolutionary Genomics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.45/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolutionary Genomics  (OTCPK:FNAM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Evolutionary Genomics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines